Thursday, November 19, 2020
9:36 AM EST – Better Plant Sciences Inc. : Announced that its majority owned subsidiary NeonMind Biosciences Inc. has now commenced a psilocybin preclinical trial examining psilocybin as a potential treatment to promote and cause weight loss and to reduce food cravings after obtaining Health Canada approval. The Trial is being conducted by the University of British Columbia pursuant to a fee for service agreement. “We are thrilled to be moving forward with our preclinical trial,” said Penny White, CEO of Better Plant. “We plan to use the data from this trial to support our pending patents and to help inform the protocol development for a Phase 2 human trial.” Better Plant Sciences Inc. (C.PLNT) shares were unchanged at 0.07.
Stocks in Play: Better Plant Sciences Inc., Thu, 19 Nov 2020 09:45:01 EST